Cargando…
Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1)
Low-dose metronomic (LDM) chemotherapy is an alternative to conventional chemotherapy and is the most frequently used approach in low dose chemotherapy regimens. The selection of patients, drug dosages, and dosing intervals in LDM is empirical. In this study, we systematically examined the schedule-...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522273/ https://www.ncbi.nlm.nih.gov/pubmed/36174026 http://dx.doi.org/10.1371/journal.pone.0274911 |
_version_ | 1784800028192145408 |
---|---|
author | Rosero, Gustavo Pattarone, Gisela Peñaherera, Ana Pilz, Julia Bödecker, Joschka Perez, Maximiliano Mertelsmann, Roland Lerner, Betiana Follo, Marie |
author_facet | Rosero, Gustavo Pattarone, Gisela Peñaherera, Ana Pilz, Julia Bödecker, Joschka Perez, Maximiliano Mertelsmann, Roland Lerner, Betiana Follo, Marie |
author_sort | Rosero, Gustavo |
collection | PubMed |
description | Low-dose metronomic (LDM) chemotherapy is an alternative to conventional chemotherapy and is the most frequently used approach in low dose chemotherapy regimens. The selection of patients, drug dosages, and dosing intervals in LDM is empirical. In this study, we systematically examined the schedule-dependent interaction of drugs on a breast cancer cell line (BCC) cultured in chambered coverslips. The LDM studies were combined with cell staining in order to better characterize different cell states and cell death modes, including caspase-dependent apoptosis, caspase-independent cell death and autophagy-dependent cell death. Microscope images were examined using the Fiji Trainable Weka Segmentation plugin to analyse cell area in 7500 images showing different modes of cell death. Paclitaxel combined with LDM chemotherapy demonstrated a reduction in the area covered by live cells. In contrast, there was an induction of high levels of cell death due to caspase-dependent apoptosis. |
format | Online Article Text |
id | pubmed-9522273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-95222732022-09-30 Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1) Rosero, Gustavo Pattarone, Gisela Peñaherera, Ana Pilz, Julia Bödecker, Joschka Perez, Maximiliano Mertelsmann, Roland Lerner, Betiana Follo, Marie PLoS One Research Article Low-dose metronomic (LDM) chemotherapy is an alternative to conventional chemotherapy and is the most frequently used approach in low dose chemotherapy regimens. The selection of patients, drug dosages, and dosing intervals in LDM is empirical. In this study, we systematically examined the schedule-dependent interaction of drugs on a breast cancer cell line (BCC) cultured in chambered coverslips. The LDM studies were combined with cell staining in order to better characterize different cell states and cell death modes, including caspase-dependent apoptosis, caspase-independent cell death and autophagy-dependent cell death. Microscope images were examined using the Fiji Trainable Weka Segmentation plugin to analyse cell area in 7500 images showing different modes of cell death. Paclitaxel combined with LDM chemotherapy demonstrated a reduction in the area covered by live cells. In contrast, there was an induction of high levels of cell death due to caspase-dependent apoptosis. Public Library of Science 2022-09-29 /pmc/articles/PMC9522273/ /pubmed/36174026 http://dx.doi.org/10.1371/journal.pone.0274911 Text en © 2022 Rosero et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Rosero, Gustavo Pattarone, Gisela Peñaherera, Ana Pilz, Julia Bödecker, Joschka Perez, Maximiliano Mertelsmann, Roland Lerner, Betiana Follo, Marie Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1) |
title | Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1) |
title_full | Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1) |
title_fullStr | Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1) |
title_full_unstemmed | Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1) |
title_short | Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1) |
title_sort | metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (jimt-1) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522273/ https://www.ncbi.nlm.nih.gov/pubmed/36174026 http://dx.doi.org/10.1371/journal.pone.0274911 |
work_keys_str_mv | AT roserogustavo metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1 AT pattaronegisela metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1 AT penahereraana metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1 AT pilzjulia metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1 AT bodeckerjoschka metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1 AT perezmaximiliano metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1 AT mertelsmannroland metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1 AT lernerbetiana metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1 AT follomarie metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1 |